RxDoctor Payments DataLook up a doctor →

Thomas Martin, MD

Internal Medicine · San Francisco, CANPI 1649234790

Payments from drug & device makers

$13,677,927in general payments, 2019–2025

Across 542 payments — averaging $25,236 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Research & Development, LLC$3.9M
  • Amgen$3.5M
  • Sanofi US Services Inc.$3.1M
  • Sanofi$1.3M
  • Pfizer$917K
  • Bristol Myers Squibb$455K
  • plus $540K from 18 others
$49,259in research payments, 2019–2025

Across 64 payments — averaging $769.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi$38K
  • Amgen$6K
  • F. Hoffmann-la Roche AG$3K
  • Sanofi-aventis U.S. LLC$2K

What the payments were for

  • Consulting fees$38,18346%
  • Speaking & faculty fees$37,00644%
  • Grants$2710%
  • Travel & lodging$5,9077%
  • Food & beverage$1,8202%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,677,927 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$392,492
Medicare patients
269
Services billed
7,957

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PomalystPomalidomide116$2,314,654
RevlimidLenalidomide87$1,665,743
VenclextaVenetoclax31$529,677
BrukinsaZanubrutinib26$389,252
Lenalidomide18$249,350
XareltoRivaroxaban16$20,964
Atovaquone24$11,836
Acyclovir170$5,434
Potassium Chloride27$1,052
Dexamethasone46$869
Gabapentin28$817
Dapsone17$805
ValacyclovirValacyclovir Hcl11$743
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen16$559
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim76$519

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Pomalyst$388,204$2,314,654116 claims
Bristol Myers SquibbRevlimid$455,185$1,665,74387 claims
AbbVieVenclexta$46$529,67731 claims
Johnson & JohnsonXarelto$282$20,96416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →